Overexpression of protease inhibitor-dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivo

Cancer Science

Volumn 100, Issue 3, 2009, Pages 434-440

  Devoogdt, Nick ^a,b   Rasool, Nabila ^a   Hoskins, Ebony ^a   Simpkins, Fiona ^a   Tchabo, Nana ^a   Kohn, Elise C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

LEUKOCYTE ELASTASE; PROGRANULIN; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; GRN PROTEIN, HUMAN; PLASMIN; SIGNAL PEPTIDE; SLPI PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MUTANT; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN SECRETION; RISK FACTOR; TUMOR XENOGRAFT; WILD TYPE; ANIMAL; ANOIKIS; ENZYMOLOGY; GENE EXPRESSION; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; METABOLISM; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; WESTERN BLOTTING;

ANIMALS; ANOIKIS; BLOTTING, WESTERN; CELL PROLIFERATION; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, NUDE; OVARIAN NEOPLASMS; PLASMIN; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR;

EID: 62849105134     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01076.x     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA: A cancer journal for clinicians 2008; 58(2): 71-96.
2. Devoogdt N, Revets H, Ghassabeh GH, De Baetselier P. Secretory leukocyte protease inhibitor in cancer development. Ann N Y Acad Sci 2004; 1028: 380-9.
3. Hough CD, Cho KR, Zonderman AB, Schwartz DR, Morin PJ. Coordinately up-regulated genes in ovarian cancer. Cancer Res 2001; 61(10): 3869-76.
4. Shigemasa K, Tanimoto H, Underwood LJ et al. Expression of the protease inhibitor antileukoprotease and the serine protease stratum corneum chymotryptic enzyme (SCCE) is coordinated in ovarian tumors. Int J Gynecol Cancer 2001; 11(6): 454-61.
5. Israeli O, Goldring-Aviram A, Rienstein S et al. In silico chromosomal clustering of genes displaying altered expression patterns in ovarian cancer. Cancer Genet Cytogenet 2005; 160(1): 35-42.
6. Tanner MM, Grenman S, Koul A et al. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res 2000; 6(5): 1833-9.
7. Tsukishiro S, Suzumori N, Nishikawa H, Arakawa A, Suzumori K. Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis. Gynecol Oncol 2005; 96(2): 516-9.
8. Doumas S, Kolokotronis A, Stefanopoulos P. Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor. Infect Immun 2005; 73(3): 1271-4.
9. Eisenberg SP, Hale KK, Heimdal P, Thompson RC. Location of the protease-inhibitory region of secretory leukocyte protease inhibitor. J Biol Chem 1990; 265(14): 7976-81.
10. Simpkins FA, Devoogdt NM, Rasool N et al. The alarm anti-protease, secretory leukocyte protease inhibitor, is a proliferation and survival factor for ovarian cancer cells. Carcinogenesis 2008; 29(3): 466-72.
11. Bouchard D, Morisset D, Bourbonnais Y, Tremblay GM. Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol 2006; 7(2): 167-74.
12. Devoogdt N, Hassanzadeh Ghassabeh G, Zhang J, Brys L, De Baetselier P, Revets H. Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proc Natl Acad Sci USA 2003; 100(10): 5778-82.
13. Devoogdt N, Revets H, Kindt A, Liu YQ, De Baetselier P, Ghassabeh GH. The tumor-promoting effect of TNF-{alpha] involves the induction of secretory leukocyte protease inhibitor. J Immunol 2006; 177(11): 8046-52.
14. Wang N, Thuraisingam T, Fallavollita L, Ding A, Radzioch D, Brodt P. The secretory leukocyte protease inhibitor is a type 1 insulin-like growth factor receptor-regulated protein that protects against liver metastasis by attenuating the host proinflammatory response. Cancer Res 2006; 66(6): 3062-70.
15. Sugino T, Yamaguchi T, Ogura G et al. The secretory leukocyte protease inhibitor (SLPI) suppresses cancer cell invasion but promotes blood-borne metastasis via an invasion-independent pathway. J Pathol 2007; 212(2): 152-60.
16. Jones MB, Michener CM, Blanchette JO et al. The granulin-epithelin precursor/PC-cell-derived growth factor is a growth factor for epithelial ovarian cancer. Clin Cancer Res 2003; 9(1): 44-51.
17. Jones MB, Spooner M, Kohn EC. The granulin-epithelin precursor: A putative new growth factor for ovarian cancer. Gynecol Oncol 2003; 88(1 Part 2): S136-9.
18. He Z, Ismail A, Kriazhev L, Sadvakassova G, Bateman A. Progranulin (PC-cell-derived growth factor/acrogranin) regulates invasion and cell survival. Cancer Res 2002 October 1; 62(19): 5590-6.
19. Kamrava M, Simpkins F, Alejandro E, Michener C, Meltzer E, Kohn EC. Lysophosphatidic acid and endothelin-induced proliferation of ovarian cancer cell lines is mitigated by neutralization of granulin-epithelin precursor (GEP), a prosurvival factor for ovarian cancer. Oncogene 2005; 24(47): 7084-93.
20. Miyanishi M, Mandai M, Matsumura N et al. Immortalized Ovarian Surface Epithelial Cells Acquire Tumorigenicity Acrogranin Gene Overexpression Oncol Reports 2007; 17 (2): 329-33.
21. Matsumura N, Mandai M, Miyanishi M et al. Oncogenic property of acrogranin in human uterine leiomyosarcoma: Direct evidence of genetic contribution in in vivo tumorigenesis. Clin Cancer Res 2006; 12(5): 1402-11.
22. Baker M, Mackenzie IR, Pickering-Brown SM et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006; 442 (7105): 916-9.
23. Van Damme P, Van Hoecke A, Lambrechts D et al. Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Bio 2008; 181(1): 37-41.
24. Zhu J, Nathan C, Jin W, Sim D et al. Conversion of proepithelin to epithelins: Roles of SLPI and elastase in host defense and wound repair. Cell 2002; 111(6): 867-78.
25. Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol 2001; 13(5): 555-62.
26. Eder AM, Sasagawa T, Mao M, Aoki J, Mills GB. Constitutive and lysophosphatidic acid (LPA) - Induced LPA production: Role of phospholipase D and phospholipase A2. Clin Cancer Res 2000; 6(6): 2482-91.
27. Zhang Y, DeWitt DL, McNeely TB, Wahl SM, Wahl LM. Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases. J Clin Invest 1997; 99(5): 894-900.
28. Ashcroft GS, Lei K, Jin W et al. Secretory Leukocyte Protease Inhibitor Med Non-Redundant Functions Necessary for Normal Wound Healing Nat Med 2000; 6(10): 1147-53.
29. Davidson B, Alejandro E, Florenes VA et al. Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma. Cancer 2004; 100(10): 2139-47.